Status:

COMPLETED

BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

Lead Sponsor:

Eikon Therapeutics

Conditions:

Tumor, Solid

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-...

Detailed Description

BDB001-201 is a multi-center, open-label, multi-arm Phase II study evaluating an experimental immunotherapy drug called BDB001. BDB001 is a Toll-like receptor 7/8 (TLR7/8) agonist delivered intravenou...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Histologically or cytologically confirmed: Cutaneous SCC, Head and Neck SCC, Melanoma, Merkel Cell Carcinoma, NSCLC, Renal Cell Carcinoma, or Urothelial Carcinoma. Other tumor types will be allowed at Sponsor's discretion.
  • Tumor progression on the most recent line of treatment with anti-PD-1 or anti-PD-L1 mAb as monotherapy or in combination.
  • Eastern Cooperative Oncology Group (ECOG) score of 0 - 2
  • At least 1 lesion with measurable disease at baseline
  • Availability of a lesion for biopsy and consent to allow pre-treatment tumor biopsy.
  • Exclusion Criteria
  • Participants are excluded from the study if any of the following criteria apply:
  • Greater than 4 lines of prior DNA-damaging chemotherapies.
  • Uncontrolled CNS metastases.
  • Active autoimmune disease.
  • Other protocol defined inclusion/exclusion criteria could apply

Exclusion

    Key Trial Info

    Start Date :

    August 30 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2023

    Estimated Enrollment :

    1 Patients enrolled

    Trial Details

    Trial ID

    NCT04819373

    Start Date

    August 30 2021

    End Date

    May 1 2023

    Last Update

    November 12 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    M D Anderson Cancer Center

    Houston, Texas, United States, 77030